AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
February 28, 2020- Study did not demonstrate statistically significant improvement in the primary endpoint of overall survival (OS) (Hazard Ratio [HR]=0.75, [95% CI 0.52 - 1.07], p=0.11)
-
February 20, 2020
-
February 19, 2020
-
February 07, 2020- Reports Full-Year Diluted EPS of $5.28 on a GAAP Basis, an Increase of 44.3 Percent; Adjusted Diluted EPS of $8.94, an Increase of 13.0 Percent
-
February 05, 2020- In this large Phase 3 study, RINVOQ™ (upadacitinib; 15 mg and 30 mg, once daily) met the primary endpoint of ACR20 response at week 12 versus placebo in adult patients with active psoriatic arthritis[1]
-
January 31, 2020- If approved by the European Commission (EC), MAVIRET will be the only pan-genotypic (GT1-6) 8-week treatment option for treatment-naïve, chronic hepatitis C (HCV) patients, without cirrhosis or with compensated cirrhosis
-
January 31, 2020- If approved by the European Commission (EC), VENCLYXTO® plus obinutuzumab would be the first chemotherapy-free, combination regimen given with a fixed duration for patients with previously untreated chronic lymphocytic leukemia (CLL)
-
January 27, 2020Agreements Contingent on FTC and European Commission Approval and Completion of AbbVie's Pending Acquisition of Allergan
-
January 14, 2020- SKYRIZI™ (risankizumab) met both primary and all secondary endpoints in a head-to-head, open-label study versus Cosentyx® (secukinumab)[1]
-
December 18, 2019- Approval supported by data from the pivotal Phase 3 SELECT rheumatoid arthritis program evaluating nearly 4,400 patients[1-5]
-
December 08, 2019- Four-year updated analysis from the MURANO trial showed an 81% reduction in the risk of disease progression or death in patients treated with VENCLEXTA®/VENCLYXTO® (venetoclax) plus rituximab (VenR) and higher rates of minimal residual disease (MRD)-negativity compared to bendamustine plus rituximab (BR)[1]
-
December 07, 2019- With extended follow-up of up to 7.5 years, treatment with IMBRUVICA early on in therapy demonstrated higher rates of progression-free survival and complete response
-
December 07, 2019- Follow-up data from Phase 3 E1912 study (abstract #33) evaluating IMBRUVICA in combination with rituximab versus standard chemoimmunotherapy (FCR) showed that previously untreated patients (aged 70 or younger) with CLL lived longer and with sustained benefit, with superior progression-free survival and overall survival - two critical measures in oncology treatment success
-
December 07, 2019- New results from the Phase 2 CAPTIVATE clinical trial show the potential of this fixed-duration, combination therapy for CLL patients starting treatment for the first time
-
November 21, 2019- AbbVie will present more than 40 abstracts featuring data from approved and investigational medicines
-
November 12, 2019
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
